Ask Me?
× The Covid-19 outbreak has no major impact on Helpinghand-pharmacy's activities. However, depending on the region, there may be slight shipping delays.
  • Free shipping for orders more than €200
  • Discreet packaging. Secure and confidential
  • 100% moneyback guarantee
  • No prescription required
Klonopin (Clonazepam)
Klonopin (Clonazepam)

* For illustration purpose only

Klonopin (Clonazepam)

$149.16

In Stock

Commercial Name: Klonopin, Rivotril
Principal Ingredient: Clonazepam
Utilization: Anti-Anxiety
Available Dosage: 0,5 mg, 1 mg, 2 mg


This product is shipped from EU


Category: Anti-Anxiety
Delivery information
No delivery to USA
no_delivery_usa

This product is currently viewed by 12 users.

Last purchase 46 minutes ago.

Dosage Quantity Price To Cart
2 mg (EU2EU) 30 pills $149.16
2 mg (EU2EU) 60 pills $275.89
2 mg (EU2EU) 90 pills $388.04
2 mg (EU2EU) 120 pills $468.79
2 mg (EU2EU) 180 pills $603.37
2 mg (EU2EU) 270 pills $765.98
2 mg (EU2EU) 360 pills $948.79
Description
        Klonopin is useful alone or as an adjunct in the treatment of the Lennox-Gastaut syndrome (petit mal variant), akinetic, and myoclonic seizures. In patients with absence seizures (petit mal) who have failed to respond to succinimides, Klonopin may be useful.

SIDE EFFECTS
The adverse experiences for Klonopin are provided separately for patients with seizure disorders and panic disorder.

Seizure Disorders
        The most frequently occurring side effects of Klonopin are referable to CNS depression. Experience in treatment of seizures has shown that drowsiness has occurred in approximately 50% of patients and ataxia in approximately 30%. In some cases, these may diminish with time; behaviour problems have been noted in approximately 25% of patients. Others, listed by system, including those identified during postapproval use of Klonopin are:
Cardiovascular: Palpitations
Dermatologic: Hair loss, hirsutism, skin rash, ankle and facial oedema
Gastrointestinal: Anorexia, coated tongue, constipation, diarrhoea, dry mouth, encopresis, gastritis, increased appetite, nausea, sore gums
Genitourinary: Dysuria, enuresis, nocturia, urinary retention
Hematopoietic: Anemia, leukopenia, thrombocytopenia, eosinophilia
Hepatic: Hepatomegaly, transient elevations of serum transaminases and alkaline phosphatase
Musculoskeletal: Muscle weakness, pains
Miscellaneous: Dehydration, general deterioration, fever, lymphadenopathy, weight loss or gain
Neurologic: Abnormal eye movements, aphonia, choreiform movements, coma, diplopia dysarthria, dysdiadochokinesis, ‘‘glassy-eyed’’ appearance, headache, hemiparesis, hypotonia, nystagmus, respiratory depression, slurred speech, tremor, vertigo
Psychiatric: Confusion, depression, amnesia, hysteria, increased libido, insomnia, psychosis (the behaviour effects are more likely to occur in patients with a history of psychiatric disturbances).
The following paradoxical reactions have been observed: irritability, aggression, agitation, nervousness, hostility, anxiety, sleep disturbances, nightmares, abnormal dreams, hallucinations.
Respiratory: Chest congestion, rhinorrhea, shortness of breath, hypersecretion in upper respiratory passages

Panic Disorder
        Adverse events during exposure to Klonopin were obtained by spontaneous report and recorded by clinical investigators using the terminology of their own choosing. Consequently, it is not possible to provide a meaningful estimate of the proportion of individuals experiencing adverse events without first grouping similar types of events into a smaller number of standardized event categories. In the tables and tabulations that follow, CIGY dictionary terminology has been used to classify reported adverse events, except in certain cases in which redundant terms were collapsed into more meaningful terms, as noted below.

        The stated frequencies of adverse events represent the proportion of individuals who experienced, at least once, a treatment-emergent adverse event of the type listed. An event was considered treatment-emergent if it occurred for the first time or worsened while receiving therapy following baseline evaluation.

Adverse Findings Observed In Short-Term, Placebo-Controlled Trials
Adverse Events Associated With Discontinuation Of Treatment
Overall, the incidence of discontinuation due to adverse events was 17% in Klonopin compared to 9% for placebo in the combined data of two 6- to 9-week trials.


Josette-Davignon

Medically reviewed by

Dr. Josette Davignon

Last updated: 26.11.2020

Write your review